PT3107914T - Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos - Google Patents

Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Info

Publication number
PT3107914T
PT3107914T PT15706282T PT15706282T PT3107914T PT 3107914 T PT3107914 T PT 3107914T PT 15706282 T PT15706282 T PT 15706282T PT 15706282 T PT15706282 T PT 15706282T PT 3107914 T PT3107914 T PT 3107914T
Authority
PT
Portugal
Prior art keywords
pyrazolo
pyrimidine
therapeutic use
diamine compounds
cdk inhibitors
Prior art date
Application number
PT15706282T
Other languages
English (en)
Inventor
Bondke Alexander
kroll Sebastian
Barrett Anthony
Fuchter Matthew
Slafer Brian
Ali Simak
Coombes Charles
Patrick Snyder James
Original Assignee
Univ Emory
Cancer Research Tech Ltd
Ip2Ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Cancer Research Tech Ltd, Ip2Ipo Innovations Ltd filed Critical Univ Emory
Publication of PT3107914T publication Critical patent/PT3107914T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT15706282T 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos PT3107914T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use

Publications (1)

Publication Number Publication Date
PT3107914T true PT3107914T (pt) 2019-05-20

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15706282T PT3107914T (pt) 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Country Status (23)

Country Link
US (4) US9932344B2 (pt)
EP (1) EP3107914B8 (pt)
JP (1) JP6498212B2 (pt)
CN (1) CN106103445B (pt)
AU (1) AU2015220560B2 (pt)
BR (1) BR112016018633B1 (pt)
CA (1) CA2939786C (pt)
CY (1) CY1121588T1 (pt)
DK (1) DK3107914T3 (pt)
ES (1) ES2721268T3 (pt)
GB (1) GB201403093D0 (pt)
HR (1) HRP20190685T1 (pt)
HU (1) HUE043122T2 (pt)
LT (1) LT3107914T (pt)
ME (1) ME03427B (pt)
NZ (1) NZ724323A (pt)
PL (1) PL3107914T3 (pt)
PT (1) PT3107914T (pt)
RS (1) RS58704B1 (pt)
SI (1) SI3107914T1 (pt)
SM (1) SMT201900266T1 (pt)
TR (1) TR201905647T4 (pt)
WO (1) WO2015124941A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2966164C (en) 2014-10-31 2023-10-17 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
JP6596090B2 (ja) 2014-12-17 2019-10-23 キングス カレッジ ロンドン レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物
CN107801397B (zh) * 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
MX394157B (es) 2015-06-15 2025-03-24 Ube Corp Derivado de dihidropirrolopirazol sustituido.
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
JP6832430B2 (ja) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞代謝過程の阻害剤
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
WO2019035866A1 (en) * 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
KR20200141487A (ko) * 2018-04-11 2020-12-18 주식회사 큐리언트 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체
US11447493B2 (en) 2018-05-02 2022-09-20 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
EP3813819A4 (en) 2018-06-29 2022-08-17 Kinnate Biopharma Inc. CYCLIN-DEPENDENT KINASE INHIBITORS
US11155560B2 (en) * 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
EP3885347B1 (en) 2018-11-14 2023-11-22 UBE Corporation Dihydropyrrolopyrazole derivative
CN109860354B (zh) * 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
WO2020186196A1 (en) * 2019-03-13 2020-09-17 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
US12398132B2 (en) * 2019-07-10 2025-08-26 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents
WO2021087138A1 (en) * 2019-10-29 2021-05-06 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201918541D0 (en) * 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2021176045A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
EP4282868B1 (en) * 2021-01-22 2026-03-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
JP2024543136A (ja) * 2021-11-24 2024-11-19 クロノス バイオ インコーポレイテッド （１Ｓ，３Ｓ）－Ｎ１－（５－（ペンタン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－７－イル）シクロペンタン－１，３－ジアミンの多形性形態および塩形態
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
TW202500147A (zh) 2023-06-27 2025-01-01 美商亞文納營運公司 雌激素受體降解劑與ｃｄｋ７抑制劑之組合
WO2025057087A1 (en) 2023-09-11 2025-03-20 Assia Chemical Industries Ltd. Solid state forms of samuraciclib
WO2025208097A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2025208104A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026057043A1 (zh) * 2024-09-14 2026-03-19 正大天晴药业集团股份有限公司 作为cdk抑制剂的三并环化合物及其应用
EP4717312A1 (en) * 2024-09-27 2026-04-01 Perha Pharmaceuticals Pyrazolo[1,5-a]pyrimidine derivatives useful as a medicament

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
CA2513684A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7557110B2 (en) 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
AU2008261027A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
JP5802676B2 (ja) * 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
EP3812387A1 (en) * 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
PL3107914T3 (pl) 2019-09-30
US10414772B2 (en) 2019-09-17
TR201905647T4 (tr) 2019-05-21
CA2939786A1 (en) 2015-08-27
US11566029B2 (en) 2023-01-31
EP3107914A1 (en) 2016-12-28
CN106103445A (zh) 2016-11-09
US20160362410A1 (en) 2016-12-15
CN106103445B (zh) 2019-08-09
US10927119B2 (en) 2021-02-23
US9932344B2 (en) 2018-04-03
AU2015220560A1 (en) 2016-10-06
CY1121588T1 (el) 2020-05-29
LT3107914T (lt) 2019-05-27
US20210253583A1 (en) 2021-08-19
JP2017506250A (ja) 2017-03-02
EP3107914B8 (en) 2019-07-17
ES2721268T3 (es) 2019-07-30
US20200055862A1 (en) 2020-02-20
BR112016018633B1 (pt) 2022-08-30
AU2015220560B2 (en) 2019-05-16
CA2939786C (en) 2022-03-08
US20180273540A1 (en) 2018-09-27
DK3107914T3 (en) 2019-04-29
HUE043122T2 (hu) 2019-08-28
BR112016018633A2 (pt) 2017-08-08
NZ724323A (en) 2022-02-25
SMT201900266T1 (it) 2019-07-11
ME03427B (me) 2020-01-20
JP6498212B2 (ja) 2019-04-10
GB201403093D0 (en) 2014-04-09
RS58704B1 (sr) 2019-06-28
SI3107914T1 (sl) 2019-05-31
HRP20190685T1 (hr) 2019-06-14
WO2015124941A1 (en) 2015-08-27
EP3107914B1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
LT3107914T (lt) Pirazolo[1,5-a]pirimidin-5,7-diamino junginiai kaip cdk inhibitoriai ir jų terapinis panaudojimas
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1245247A1 (zh) 溴结构域的抑制剂
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
ZA201800485B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
ZA201701207B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
IL258070A (en) Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide
IL253427A0 (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose